In this study, we investigated whether elimination of CD4+ CD25+ Tregs using anti-CD25 mAbs (PC61) was capable of enhancing CCL21-mediated antitumor immunity in a mouse HCC model. The gene discussed is IL2RA; the disease is hepatocellular carcinoma.